Immunotherapy as a second-line or later treatment modality for advanced non-small cell lung cancer: A review of safety and efficacy
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference40 articles.
1. Prognostic value of PDL1 expression in stage III non-small cell lung cancer (NSCLC) treated by chemo-radiotherapy (CRT);Adam;Eur. J. Cancer,2015
2. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: a Bayesian network meta-analysis;Almutairi;Crit. Rev. Oncol. Hematol.,2019
3. Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC);Antonia;Ann. Oncol.,2016
4. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer;Antonia;Reply. N Engl J Med,2019
5. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC;Antonia;N. Engl. J. Med.,2018
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Treatment: Quo Vadis?;International Journal of Molecular Sciences;2024-06-07
2. The CCL27-CCR10 axis contributes to promoting proliferation, migration, and invasion of lung squamous cell carcinoma;HISTOL HISTOPATHOL;2023
3. Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors;PeerJ;2022-12-15
4. Guidelines on lung adenocarcinoma prognosis based on immuno-glycolysis-related genes;Clinical and Translational Oncology;2022-11-29
5. Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment;OncoTargets and Therapy;2022-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3